Gilead appoints Dr. Muzammil M. Mansuri as SVP, R&D
Gilead Sciences, has appointed Muzammil M. (“Muz”) Mansuri, PhD, to senior vice president, research and development strategy and corporate development, a role that expands his current responsibilities to include leadership of corporate development and alliance management.
Mansuri joined Gilead in July 2010, following the company’s acquisition of CGI Pharmaceuticals. Prior to joining Gilead, Mansuri served as the chief executive officer or chief operating officer at several biotechnology companies, including CGI, BIKAM Pharmaceuticals, Sequoia Pharmaceuticals, GPC Biotech and Mitotix. He also was a general partner with Flagship Ventures and served on the boards of CGI, AVEO Pharmaceuticals, BG Medicine and Adaptive Therapeutics.